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Abstract
Background: In Mozambique, there is limited data regarding the monitoring of Tuberculosis (TB) treatment results
and determinants of adverse outcomes under routine surveillance conditions. The objectives of this study were to
evaluate treatment outcomes among TB patients, analyze factors associated with a fatal outcome and determine
the proportion of deaths attributable to TB in the district of Manhiça, Southern Mozambique.
Methods: This is a retrospective observational study based on TB patients diagnosed in the period 2011–2012. We
used three different data sources: a) TB related variables collected by the National TB Control Program in the district
of Manhiça for all TB cases starting treatment in the period 2011–2012. b) Population estimates for the district were
obtained through the Mozambican National Statistics Institute. c) Deaths and other relevant demographic variables
were collected from the Health and Demographic Surveillance System at Manhiça Health Research Center. WHO
guidelines were used to define TB cases and treatment outcomes.
Results: Of the 1957 cases starting TB treatment in the period 2011–2012, 294 patients (15.1 %) died during
anti-tuberculous treatment. Ten per cent of patients defaulted treatment. The proportion of patients considered
to have treatment failure was 1.1 %. HIV infection (OR 2.73; 95 % CI: 1.70–4.38), being female (OR: 1.39; 95 % CI: 1.31–1.
91) and lack of laboratory confirmation (OR 1.51; 95 % CI: 1.10–2.08) were associated with dying during the course of
TB treatment (p value <0.05). The contribution of TB to the overall death burden of the district for natural reasons was
6.5 % (95 % CI: 5.5–7.6), higher for males than for females (7.8 %; 95 % CI: 6.1–9.5 versus 5.4 %; 95 % CI: 4.1–6.8
respectively). The age group within which TB was responsible for the highest proportion of deaths was 30–34 among
males and 20–24 among females (20 % of all deaths in both cases).
Conclusion: This study shows a very high proportion of fatal outcomes among TB cases starting treatment. There is
a high contribution of TB to the overall causes of mortality. These results call for action in order to improve
TB (and TB/HIV) management and thus treatment outcomes of TB patients.
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Background
Tuberculosis (TB) remains an important public health
concern and a leading cause of disease and death world-
wide. According to the last global TB report it accounts
for 9 million new cases and 1.5 million deaths per year
[1]. Most of these deaths occur in Sub-Saharan Africa.
Mozambique is one of the 22 high burden TB countries
and, among the countries on that list, ranks third on
high HIV co-infection rates with 56 % of TB patients
being HIV positive [1]. The HIV epidemic, which has
stricken the country deeply, hinders the millennium
development goal of halting and beginning to reverse
the incidence of TB by 2015 at a country level; a goal
now achieved by most countries in the world.
Among the many challenges for TB control in
Mozambique, ensuring proper TB diagnosis and treat-
ment as well as implementing the one-stop model for
* Correspondence: alberto.garcia-basteiro@manhica.net
1Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique
2ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat
de Barcelona, Barcelona, Spain
Full list of author information is available at the end of the article
© 2016 García-Basteiro et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
García-Basteiro et al. BMC Infectious Diseases  (2016) 16:214 
DOI 10.1186/s12879-016-1534-y
TB and HIV care has been regarded as a national prior-
ity [2, 3]. A recent study conducted in Mozambique’s
second largest city showed that patient and health sys-
tem delay prior to TB treatment initiation is on average
150 days, which favors adverse outcomes during TB
treatment [4]. In 2013, approximately 56,000 deaths
were attributable to TB, although precise estimates are
not available due the predictably low case detection rate
and lack of information on cause of death, especially in
people living with HIV [1]. Estimates at the national
level speak of a treatment success rate (treatment
complete and cured) of 87 % among the general popula-
tion, which still does not meet the global targets for
treatment success, set at 90 % by 2015 [5]. Worryingly,
recent data from Manhiça district, in the south of the
country, show an alarming mortality rate among adult
TB cases co-infected with HIV [6]. The potential threat
of increasing multi-drug resistance (MDR) numbers in
the country, around 3.5 % among new cases according
to the last national survey [7], could further jeopardize
the achievement of the treatment success targets set in
the strategic plan 2014–2018 by the National TB Control
Program (NTP) [8].
Very little data are available in the country regarding
the monitoring of treatment results and determinants of
adverse outcomes under routine surveillance conditions.
Knowledge on the burden of deaths attributable to TB
among all causes of mortality is needed in order to set
public health policy and prioritize interventions. The
main objective of this study was to evaluate the treat-
ment outcomes among TB patients and analyze factors
associated with a fatal outcome. As a secondary object-
ive, we estimated the proportion of deaths attributable
to TB in a very high HIV- and TB-burden area in south-
ern Mozambique.
Methods
This is a retrospective observational study based on rou-
tine NTP data from TB patients diagnosed from January
2011 to December 2012 in the district of Manhiça,
Southern Mozambique.
Study area
The study was conducted at Manhiça Health Research
Center (CISM from its acronym in Portuguese), located
in the district of Manhiça, in Maputo province. CISM
has a health and demographic surveillance system
(HDSS) in the so-called ‘study area’, which at the time of
this study was following approximately 92,000 individ-
uals (covering around 53 % of the district population)
living in 20,000 geo-positioned households. The system
monitors important demographic events, such as births,
deaths, migration movements and pregnancies, allowing
for precise population estimates. An update of the health
profile of the study area has been recently published
elsewhere [9].
The prevalence of HIV infection in adults aged 18–47
was 39.9 % in 2010 [10] and the incidence of smear-
positive TB among young adults living with HIV was
847 per 100,000 in 2011 [6]. A recent community inci-
dence study in children under 3 revealed a minimum
community incidence of 470 per 100,000 for this age
group [11].
Data sources
All TB related variables included in this study are part of
the routine information collected by the NTP in the dis-
trict of Manhiça for TB cases diagnosed in the period
2011–2012. Briefly, the NTP had, at that time, two of-
fices in the district where TB patients could be registered
and begin treatment: one at Manhiça’s District Hospital
(HDM), and the other at the Rural Hospital of Xinavane,
the second largest health facility in the district, which is
located 53 km North of Manhiça village. The TB surveil-
lance system is mostly passive, with non-systematic case
finding strategies limited to TB contacts less than 5 years
of age. Fatal outcome (death) is registered when a TB
patient dies during TB treatment. Population estimates
for the district were obtained based on the last official
census (2007) through the Mozambican National Statis-
tics Institute, and the estimated population for 2011 and
2012 using annual data from the HDSS at CISM. Demo-
graphic variables (sex, age, deaths, births, migrations) for
the entire district were obtained extrapolating data from
the HDSS to the entire district. From 2012 onwards, the
HDSS recorded the type of death in those households
who consented (accident, homicide, suicide, natural
causes, disease, etcetera) in all deaths belonging to the
study area (the proportion of TB attributable deaths
among all deaths was therefore restricted to the year
2012). All data by CISM or NTP, although not freely
available, can be accessed upon request.
TB diagnosis, procedures and case definitions
Laboratory diagnosis of TB during 2011 was made on
the basis of traditional microscopy using Ziehl-Neelsen
staining. Culture was only done at diagnosis in patients
previously treated for TB (former WHO Category 2 pa-
tients) or new TB cases who were acid-fast bacilli (AFB)
smear positive at month 5 of follow up. Most AFB
smears were processed in the Biosafety Level III labora-
tory at CISM, which was subjected to an external quality
assurance program. Other samples from the north of the
district were processed at the laboratory of the rural
hospital of Xinavane. Pulmonary TB patients with con-
firmed TB are recommended to have sputum test at
months 2 and 5 of follow up. WHO guidelines were
used to define TB cases and treatment outcomes [12].
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TB treatment is offered free of charge at central and
peripheral health units. For first line treatment, fixed
dose combinations in both the intensive and continu-
ation phase are used in all country facilities. In the
district of Manhiça, treatment is given on a weekly
basis. A godfather or family relative is advised to
oversee patient’s treatment. All children routinely re-
ceive Bacille Calmette-Guérin (BCG) vaccine at birth,
with estimated coverage ranging from 86 to 94 % [13, 14].
Data management and analysis
Data from the TB registries were entered into a Micro-
soft Access database (Microsoft Corporation, Redmond,
WA, USA). Relevant variables included unique national
TB identifier (NIT), age, name, TB diagnosis date, TB
treatment initiation date, sex, type of TB (pulmonary or
extrapulmonary), category of TB case (new/retreatment),
HIV status, antiretroviral therapy (ART), outcome, and
date of TB outcome. Data analysis was conducted using
Stata, version 13 (Stata Corporation, College Station,
TX, USA). TB profile by age and sex is depicted for the
year 2011, since during 2012, a study involving active
case finding in children under the age of three was being
conducted in the area.
Univariate and multivariable logistic regression ana-
lyses were conducted to assess the effect of the different
variables on our outcome variable “death during TB
treatment”. All variables that showed at least some evi-
dence of association (different Odds Ratio (OR) for the
different categories and a Chi square p-value for statis-
tical significance testing lower than 0.2 in the univariate
analysis) were tested in the multivariable analysis. OR
and 95 % confidence intervals and p-values were calcu-
lated. Pooled p-values were obtained for categorical vari-
ables through likelihood ratio tests. Those associations
with p value less than 0.05 were regarded as statistically
significant.
In order to build survival curves, the database contain-
ing TB surveillance data was linked with the Manhiça
HDSS database. Common variables to both databases
were used (name, age, gender and residence village). We
used deterministic and probabilistic record linkage
approaches through routines implemented in the Recor-
dLinkage package on R 3.1.1 (R Development Core
Team, Vienna, Austria). From this exercise, three lists
were produced; the first depicted those patients with a
perfect match; a second list with probable match and
the third for possible match. The “probable” and “pos-
sible” match lists required further manual verification on
the reason for discrepancy by personnel in the clinical
and demographic departments. Kaplan Meier survival
curves and log rank tests were then used to compare
survival probabilities between different categories of the
interest variable.
Results
Baseline characteristics and TB incidence rate
A total of 946 and 1011 TB cases started treatment in
the district of Manhiça during 2011 and 2012, respect-
ively. Fifty-six per cent of all cases diagnosed in the
period 2011–2012 were male. The mean age at treat-
ment initiation was 36.4 years (SD: 15.7) and 11.5 %
were children below 15 years of age. The prevalence of
HIV infection among those TB cases was 71.8 %. The
proportion of HIV patients on ART at any time during
treatment was 41.0 % (20.3 % and 62.2 % in 2011 and
2012 respectively, p <0.001). Eighty-three per cent of the
cases had pulmonary TB and 10.1 % were previously
treated for TB (Table 1). Among previously treated pa-
tients, 88.7 % were TB relapses or reinfections, 5.1 %
were starting treatment after previous treatment failure
and 6.2 % after treatment default. Thirty-three per cent
of all TB cases were confirmed by smear microscopy
(45.6 % and 2.2 % for pulmonary and extrapulmonary
TB respectively).
Incidence rates for TB (including new cases and re-
lapses) in the district of Manhiça were 540 and 571 cases
per 100,000 population for 2011 and 2012, respectively.
Incidence rates for bacteriologically confirmed TB were
212 and 218 per 100,000 population for 2011 and 2012.
The highest incidence was observed among adults, being
the highest among males aged 40–44 (2796/100,000) and
females aged 30–34 years of age (1185/100,000) (Fig. 1).
Treatment outcomes
Of all cases diagnosed with TB in the period 2011–2012,
294 patients (15.1 %) died during anti-tuberculous treat-
ment. Treatment success (cured or treatment com-
pleted) occurred in 71.2 % of all patients (including new
and retreatment cases). Ten per cent of patients
defaulted treatment. The proportion of patients consid-
ered to have treatment failure was 1.1 % (only 703/1957
underwent smear at month 5). The proportion of treat-
ment success among new cases was 72.4 %, with a suc-
cess rate of 71.0 % among HIV positive patients, and
76.6 % among those with laboratory confirmed TB.
The univariate analysis showed that HIV-infected indi-
viduals had an odds of dying during TB treatment 2.3
times higher than among HIV uninfected TB patients.
Among HIV positive patients, those who were not on
ART were more likely to die during treatment (un-
adjusted uOR: 1.78 95 % CI 1.31–2.42). The multivari-
able logistic regression analysis showed that HIV
infection (both patients on ART and not on ART, OR
1.83 95 % CI 1.07–3.14 and OR 5.50; 95 % CI: 2.13–5.74
respectively), being male (OR: 1.39; 95 % CI: 1.01–1.91)
and lack of laboratory confirmation (OR 1.54; 95 % CI:
1.12–2.13) were associated with dying during the course
of TB treatment (p value <0.05) (Table 1).
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Survival analysis
The total number of TB patients diagnosed in 2011–2012
who were linked to the demographic surveillance sys-
tem database was 395 (38.1 % of estimated TB cases
belonging to the study area). Kaplan–Meier estimates
for the probability of surviving 1 year after treatment
initiation, by HIV status, type of diagnosis, type of TB
and being on ART are presented in Fig. 2. The cumu-
lative probability of survival 6 months after TB treat-
ment initiation had begun was 0.87 and 1 year after
treatment was 0.83. Patients with TB/HIV co-infection
were less likely to be alive at the end of first year
after treatment initiation compared to TB HIV unin-
fected patients (survival probability: 0.78 and 0.93 re-
spectively, p value <0.001). Likewise, 76 % of the
extrapulmonary TB patients remained alive 1 year
after treatment initiation compared to 85 % of pul-
monary TB cases (p value <0.022).
Burden of TB associated mortality
During the year 2012, there were an estimated 2120
deaths in the district of Manhiça. Excluding violent
deaths (road and household accidents, homicides and
suicides), which accounted for 4.7 % of the total deaths,
there were 2019 estimated deaths (951 and 1068 among
males and females) attributable to disease or natural
causes. The contribution of diagnosed TB to the overall
death burden of the district for natural reasons was
6.5 % (132/2019) (95 % CI: 5.5–7.6) (Table 2), higher for
males than for females (7.8 %; 95 % CI: 6.1–9.5 versus
5.4 %; 95 % CI: 4.1–6.8 respectively), although not statis-
tically significant. The age group within which TB was
Table 1 Univariate and multivariate analysis of factors associated with death during antituberculous treatment in the district of
Manhiça (2011–2012)
Total analysed Outcome of treatment uOR (95 % CI) p value aOR (95 % CI) p value*
N# % Death N (%) Alive N (%)
Year
2011 946 48.3 157 16.6 789 83.4 Ref 0.063 Ref 0.87
2012 1011 51.7 137 13.6 871 86.4 0.79 (0.62–1.01) 1.03 (0.73–1.44)
Age
< 15 224 11.5 24 10.7 200 89.3 Ref 0.071 Ref 0.093
15–24 174 8.9 25 14.4 149 85.6 1.40 (0.77–2.54) 1.57 (0.49–5.01)
25–34 625 32.1 91 14.6 534 85.4 1.42 (0.88–2.29) 1.40 (0.48–4.01)
35–44 407 20.9 75 18.5 331 81.5 1.89 (1.15–3.09) 1.73 (0.58–5.14)
45–54 258 13.2 34 13.2 223 86.8 1.27 (0.73–2.22) 1.56 (0.51–4.77)
> 55 261 13.4 45 17.3 215 82.7 1.74 (1.03–2.97) 2.45 (0.80–7.50)
Sex
Female 856 43.9 118 13.8 738 86.2 Ref 0.15 Ref 0.041
Male 1096 56.2 176 16.1 917 83.9 1.20 (0.93–1.54) 1.39 (1.01–1.91)
AFB smear at diagnosis
Positive 750 51.7 89 11.9 658 88.1 Ref 0.005 Ref 0.009
Negative 701 48.3 120 17.1 581 82.9 1.52 (1.13–2.05) 1.54 (1.12–2.13)
TB Category
New Case 1746 89.9 260 14.9 1485 85.1 Ref 0.45
Retreatment 195 10.1 33 16.9 162 83.1 1.16 (0.78–1.73)
Type of TB
Pulmonary 1630 83.4 237 14.6 1390 85.4 Ref 0.17 Ref 0.61
Extra-pulmonary 325 16.6 57 17.5 268 82.5 1.25 (0.91–1.71) 0.87 (0.52–1.47)
HIV status
HIV uninfected 540 28.2 45 8.4 494 91.7 Ref <0.001 Ref <0.001
HIV infected not on ART 811 42.4 164 20.2 647 79.8 2.78 (1.96–3.95) 3.50 (2.13–5.74)
HIV infected on ART 563 29.4 70 12.5 491 87.5 1.56 (1.05–2.32) 1.83 (1.07–3.14)
uOR unadjusted Odd Ratio, aOR Adjusted Odds Ratio, ARV On antiretroviral treatment, AFB acid fast bacilli
*p-value obtained through likelihood ratio test (LRT)
#In some variables (age, age, sex, AFB smear, TB category and TB type and HIV status) there is missing data, because these data were not available
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Fig. 1 TB incidence rate in the district of Manhiça by sex and age group (year 2011)
Fig. 2 Kaplan-Meier survival estimates by a) HIV status b) ARV treatment c) Type of TB d) Laboratory confirmation (year 2011–2012)
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responsible for the highest proportion of deaths was
30–34 among males and 20–24 among females (20 %
of all deaths in both cases).
Discussion
This study is one of the few operational research studies
assessing TB treatment outcomes and mortality burden
attributable to TB in Mozambique. We found an ex-
tremely high fatality rate among patients on TB treat-
ment (15.1 %), much higher than recent figures from
neighboring sub-Saharan African countries [15–17].
Moreover, the general contribution of TB to the overall
causes of mortality in our district is very high (6.5 %),
skyrocketing up to one out of every five deaths among
young adult females and males in their mid-thirties.
Tuberculosis was an important cause of death in both
2011 and 2012, especially among middle age groups. Al-
though the analysis approach does not allow comparison
among other diseases, it is very likely that TB ranks
among the leading causes of death. In South Africa, dur-
ing 2013, tuberculosis was the leading cause of death, ac-
counting for 8.8 % of all deaths, and of 9.8 % of all
deaths for natural causes [18]. As in South Africa, our
study shows that the proportion of deaths due to tuber-
culosis among all deaths by natural causes was higher
for males (7.8 %) compared to females (5.4 %). Due to
the difficulty of ascertaining the actual cause of deaths of
TB patients, we have defined death due to tuberculosis
as a death occurring during TB treatment. This certainly
overestimates the true TB attributable deaths among pa-
tients on treatment, since dying during TB treatment
does not equal dying of TB. However, since our analysis
is based on deaths among notified TB cases only and
WHO estimated a case detection rate of 34 % in the
country during 2012, it is very likely that it underesti-
mated the true TB contribution to the death burden. To
accurately ascertain cause of death by TB, the only ac-
ceptable method would be the postmortem evaluation of
those cases [19, 20].
The treatment success rate (which includes those
cured or who completed treatment) in the district of
Manhiça for the period 2011–2012 was 71.2 %, and
76.6 % among those laboratory confirmed TB patients.
More than 50 % of the cases who did not achieve treat-
ment success died (defaulting, treatment failure and
transfer out cases account for the other cases). These re-
sults are far below the 87 % treatment success target set
by the Stop TB partnership for the year 2015 and even
further away from the new target (90 %) of the Global
Plan to Stop TB 2011–2015 [5]. Although at a country
level Mozambique reported treatment success rates of
87 % among new cases [1] for the year 2013 (no data are
available for 2012), the lower figures obtained in the
district of Manhiça might have different explanations.
HIV prevalence among TB cases in the district of
Manhiça has been reported to be higher than national
level estimates [6]. Our study and the literature repeat-
edly report a higher proportion of poorer outcomes
among HIV-infected individuals [15, 21–24]. Among HIV
patients, the proportion of patients on ART (at any time
during treatment) was very low (41.0 %). This contributes
to the overall poor outcomes [17, 25]. The reason behind
better treatment outcomes in 2012 than 2011 is driven
primarily by a higher proportion of patients on ART (the
Table 2 Proportion of deaths attributable to Tuberculosis in the district of Manhiça. Year 2012
All population Males Females
Age
group
Deaths
Districta
TB related
deaths
% Deaths (95 % CI)
associated to TB
Deaths
Districta
TB related
deaths
% Deaths (95 % CI)
associated to TB
Deaths
Districta
TB related
deaths
% Deaths (95 % CI)
associated to TB
0–1 232 0 0.0 (0.0–0.0) 112 0 0.0 (0.0–0.0) 120 0 0.0 (0.0–0.0)
1–4 242 5 2.1 (0.3–3.9) 112 2 1.8 (0.0–4.2) 130 3 2.3 (0.0–4.9)
5–9 56 1 1.8 (0.0–5.3) 39 0 0.0 (0.0–0.0) 17 1 5.74 (0.0–17.1)
10–14 35 1 2.9 (0.0–8.4) 23 0 0.0 (0.0–0.0) 12 1 8.6 (0.0–24.0)
15–19 40 0 0.0 (0.0–0.0) 19 0 0.0 (0.0–0.0) 21 0 0.0 (0.0–0.0)
20–24 60 11 18.3 (8.5–28.1) 19 3 15.8 (0.0–32.2) 41 8 19.7 (7.4–31.6)
25–29 104 15 14.4 (7.7–21.2) 50 9 17.9 (7.4–28.6) 54 6 11.1 (2.7–19.5)
30–34 168 30 17.9 (12.1–23.6) 95 19 20.0 (12.0–28.0) 74 11 14.9 (6.8–23.0)
35–39 162 21 13.0 (7.8–18.1) 75 12 15.9 (7.7–24.3) 87 9 10.3 (3.9–16.7)
40–44 110 15 13.6 (7.2–20.0) 66 9 13.7 (5.4–21.9) 44 6 13.5 (3.5–23.8)
45–49 108 5 4.6 (0.7–8.6) 56 3 5.3 (0.0–11.3) 52 2 3.8 (0.0–9.1)
50–54 107 9 8.5 (3.2–13.8) 37 7 19.0 (6.3–31.5) 70 2 2.9 (0.0–6.8)
≥55 594 19 3.2 (1.8–4.6) 248 10 4.0 (1.6–6.5) 346 9 2.6 (0.9–4.3)
Total 2019 132 6.5 (5.5–7.6) 951 74 7.8 (6.1–9.5) 1068 58 5.4 (4.1–6.8)
aExcluding violent or accidental deaths (car or at home), suicides and homicides
García-Basteiro et al. BMC Infectious Diseases  (2016) 16:214 Page 6 of 9
difference disappears after adjusting for HIV infection and
ART status in the multivariable regression model). Inter-
estingly, there is substantial 4 % additional mortality from
6 month to 1 year after treatment initiation (when most
patients have already finished treatment). This could be
attributable to clinical conditions related to HIV/AIDS, al-
though cannot explain all the additional mortality after
6 month treatment, since some of those deaths occurring
6 months after treatment initiation were in HIV negative
individuals. High defaulting treatment rate (10 %) and
poor adherence to TB treatment (which would translate
into longer treatment periods), but not necessarily default-
ing, could also be another factor for low success rate, al-
though the length of TB treatment was not assessed in
our study.
Those TB cases who were not laboratory confirmed
with smear microscopy had a higher odds of dying during
treatment than those who were just clinically diagnosed
(Table 1 and Fig. 2b). This might have two different expla-
nations. Some may have been misdiagnosed with TB, thus
antituberculous therapy was useless and could have de-
layed or prevented access to the correct treatment for
their condition. Another explanation would be that HIV
positive individuals have higher immunosuppression
(lower CD4 counts) and are often paucibacillary, thus less
likely to have a positive smear. This may have led to diag-
nostic delays, contributing to the poorer outcomes [26].
Although several studies have shown that re-treatment
cases are more likely to have a poor outcome [26], mostly
as a consequence of higher rates of defaulting and higher
MDR rates, we could not show this association in our
study. A potential explanation for this is that information
on previous TB treatment might have not been properly
recorded (patients’ recall bias or lack of adequate history
taking). Only 10 % of patients were classified as retreat-
ment, while, for example, in Cape Town, South Africa,
retreatment cases consistently account for 30 % of notified
TB cases [27, 28].
Although TB/HIV patients not on antiretroviral
treatment were significantly more likely to have a
fatal outcome than those taking ART (20.3 % vs
12.5 %, p < 0.001), we expected to find a greater dif-
ference [29]. Kaplan Meier survival analysis, although
conducted on a smaller sample, did not show statis-
tical differences between both groups. Besides the
small numbers, this might be due to the fact that pa-
tients who received ART were also those at highest
risk of dying (because they had low CD4 counts or
other opportunistic infections). An alternative explan-
ation could be the poor reporting on ART status be-
fore February 2012, when the HIV/TB one-stop
model was implemented in the district (HIV treat-
ment during TB treatment being provided and moni-
tored by the NTP officers). In fact the proportion of
HIV infected TB patients on ART increased sharply
from 2011 to 2012 (20 % to 62 % respectively). Thus,
some patients might have started HIV treatment dur-
ing TB treatment also in 2011, but this information
may have been poorly or not registered on the TB
registry books. In fact, a recent study in Manica Province
(Central Mozambique), reported that only 73 % of data on
ART use in the TB registry were correct [30].
This study had several limitations. The linking of the
NTP registry book with the HDSS dataset could only be
done to a subset of patients belonging to the study area,
limiting the sample size for the survival analysis. The
reasons for this are the different names used by patients,
handwriting errors on the matching variables and the
impossibility of verification on those without a perfect
matching. That said, we believe there are no sources of
selection bias in the sample used for this analysis. Sec-
ond, we could not assess the impact of other important
variables/comorbidities on mortality, such us malnutri-
tion, diabetes, occupation or immunosuppression (CD4
counts), which would provide further characterization of
TB mortality factors. Third, the aforementioned poten-
tial misreporting of use of ARTs or TB type (new case or
retreatment) calls for cautious interpretation of the mag-
nitude of association of mortality and these two vari-
ables. Fourth, during the study period, culture was not
routinely performed, thus some false positive smear re-
sults, due to non tuberculous mycobacteria (NTMs)
could have occurred. However, this might have had lim-
ited impact on treatment outcomes, since the proportion
of NTMs among positive smears from adult population
is below 2 % (unpublished data). Lastly, due to the lack
of reliable information on dates of death and defaulting
and very few deaths on the subsample that could be
linked to HDSS, Cox regression, a preferred analysis
strategy for analysis factors associated to mortality, was
not performed.
Conclusions
This study contributes to the limited surveillance-based
analyses on TB programmatic indicators at district level
in a high TB/HIV burden country. Our results show that
fatal outcomes among TB cases starting treatment are
very high. There is a need for improving the proportion
of TB/HIV cases being linked to HIV care. The study
also showed a high contribution of TB to the overall
causes of mortality suggesting that TB remains one of
the major public health problems in the country. These
results call for renewed action in order to improve man-
agement and thus treatment outcomes of TB patients.
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